RxDoctor Payments Data

John Bailey, MD

Family Medicine · Carrollton, TXNPI 1548203599

Payments from drug & device makers

$11,862in general payments, 2019–2025

Across 704 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$977
  • AstraZeneca$927
  • Pfizer$861
  • Lilly USA, LLC$641
  • GSK$534
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,862 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$32,228
Medicare patients
99
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$56,386
EliquisApixaban29$22,037
OzempicSemaglutide23$20,943
JanuviaSitagliptin Phosphate16$19,888
MounjaroTirzepatide13$12,565
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,244
Humalog Kwikpen U-100Insulin Lispro14$6,177
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,978
Sumatriptan Succinate11$1,486
SynthroidLevothyroxine Sodium21$1,407
Testosterone11$1,381
Gabapentin76$1,326
Atorvastatin Calcium181$1,322
Simvastatin164$1,081
Albuterol Sulfate HfaAlbuterol Sulfate43$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$335$56,38653 claims
PfizerEliquis$861$22,03729 claims
Novo NordiskOzempic$977$20,94323 claims
MerckJanuvia$454$19,88816 claims
Lilly USA, LLCMounjaro$641$12,56513 claims
AbbVieSynthroid$1,473$1,40721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →